185 research outputs found
The impact of the time interval from diagnosis to radical prostatectomy on oncological outcomes in high-risk prostate cancer
Introduction. To date, the impact of the time interval from diagnostic prostate biopsy to radical prostatectomy on treatment outcomes remains a topical issue.Objective. To evaluate the effect of the timespan from diagnosis to radical treatment of prostate cancer (PCa) patients on tumor morphology and long-term oncological outcomes.Materials and methods. A retrospective analysis of the results of treatment of patients with high-risk PCa who underwent radical prostatectomy with extended lymphadenectomy from 2001 to 2019 in three St. Petersburg clinics was performed. The influence of the time interval from prostate biopsy to radical treatment on long-term outcomes was assessed.Results. An increase in the time interval before surgical treatment over three months did not affect the tumor morphology. Five-year biochemical relapse-free survival was 79.7%, 67.8% and 52.5% among patients with time interval from biopsy to surgical treatment less than 30 days, 30 β 90 days and more than 90 days, respectively. The time interval prior to radical treatment did not have any effect on overall and cancer-specific survival.Conclusion. The time interval from prostate biopsy to surgical intervention, not exceeding 3 months, is the most favorable with respect to long-term outcomes
Polymorphism of ITS sequences in 35S rRNA genes in Elymus dahuricus aggregate species: two cryptic species?
Nuclear ribosomal internal transcribed spacer (ITS) sequences were sequenced for 23 species and subspecies of Elymus sensu lato collected in Russia. The Neighbor-Net analysis of ITS sequences suggested that there are four ribotypes called Core Northern St-rDNA, Core Southern St-rDNA, Northern dahuricus St-rDNA and Southern dahuricus St-rDNA. The Core Southern variant of St-rDNA is closely related to rDNA of diploid Pseudoroegneria stipifolia (PIΒ 313960) and P.Β spicata (PI 547161). The Core Northern St-rDNA is closely related to rDNA of P. cognata (PI 531720), a diploid species of Kyrgyzstan carrying StY variant of the St genome. The Core Northern St-rDNA is widespread among the Elymus species of Siberia and the Far East, including Yakutia and Chukotka. The Core Southern St-ribotype is typical of southern Elymus and Pseudoroegneria of the South Caucasus, Primorye, Pakistan, and South Korea. The Northern dahuricus St-ribotype and Southern dahuricus St-ribotype are derivatives of the Core Northern and Core Southern St-ribotypes, correspondingly. Both of them were found in all four studied species of the E. dahuricus aggregate: E. dahuricus Turcz. ex Griseb., E. franchetii Kitag., E. excelsus Turcz. ex Griseb. and Himalayan E. tangutorum (Nevski) Hand.-Mazz. In other words, there are at least two population groups (two races) of the Elymus dahuricus aggregate species that consistently differ in their ITS-sequences in Siberia, the Far East and Northern China. Each contains all morphological forms, which taxonomists now attribute either to different species of E. dahuricus aggr. (E. dahuricus sensu stricto, E. franchetii, E. tangutorum, E. excelsus) or subspecies of Campeiostachys dahurica (Turcz. ex Griseb.) B.R. Baum, J.L. Yang et C.C. Yen. At the moment it is unknown if there are any morphological differences between plants carrying either Northern or Southern dahuricus rDNA. Probably, they are cryptic species, but it is certain that if differences in morphology between the two races exist, they are not associated with signs that are now considered taxonomically significant and are used to separate E. dahuricus s. s., E. franchetii, E. tangutorum, and E. excelsus
Effect of taxanes on the miR-106 and miR-200c expression in prostate cancer cells in vivo and in vitro
Introduction. A combination of antiandrogen and cytostatic drugs was justified in the neoadjuvant therapy of patients with high-risk prostate cancer (HiRPCa) in some clinical trials. The effectiveness of such therapy in each individual case depends on the sensitivity of cancer cells to the applied drugs. It makes possible the development of the new technologies to personalize therapeutic approach. MicroRNAs (miRNAs) are a class of regulatory molecules whose expression is altered in PCa cells and can be associated with the sensitivity/resistance of cancer cells to specific cytostatics, for instance, taxanes.Objective. To identify the potential-marker miRNAs of PCa cells sensitivity to taxanes.Materials and methods. Samples of PCa tissue (n. 56) obtained from patients underwent neo-adjuvant therapy (antiandrogen and taxanes) and radical prostatectomy; PCa cell lines (PC-3, DU-145, LNCap). Total RNAs isolation was carried out using miRNeasy FFPE Kit, LRU-100-50; miRCURY LNA miRNA Focus PCR Panel, All-MIR kits were used for semi-quantitative analysis of potentially marker microRNA molecules using sequential reverse transcription and PCR.Results. The effect of taxanes on PCa cells is associated with up-regulation of miR-106b expression and down-regulation of miR-200c expression in both in vivo and in vitro conditions.Conclusion. MiR-106b and miR-200c miRNAs are involved in the response of PCa cells to taxanes, and therapeutic modification of these molecules in PCa cells may present a potential strategy to increase their sensitivity to taxane-containing therapy. Appropriate innovative technology may be in demand in the treatment of HiRPCa-patients
ΠΡΠΎΠ³ΡΠ°ΠΌΠΌΠ° ΡΠ°Π½Π½Π΅Π³ΠΎ Π²ΠΎΡΡΡΠ°Π½ΠΎΠ²Π»Π΅Π½ΠΈΡ ΠΏΡΠΈ ΡΠ°Π΄ΠΈΠΊΠ°Π»ΡΠ½ΠΎΠΌ Ρ ΠΈΡΡΡΠ³ΠΈΡΠ΅ΡΠΊΠΎΠΌ Π»Π΅ΡΠ΅Π½ΠΈΠΈ Π±ΠΎΠ»ΡΠ½ΡΡ ΡΠ°ΠΊΠΎΠΌ ΠΏΡΠ΅Π΄ΡΡΠ°ΡΠ΅Π»ΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ: ΠΎΠΏΡΡ ΡΠΏΠ΅ΡΠΈΠ°Π»ΠΈΠ·ΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠ³ΠΎ ΡΡΠ°ΡΠΈΠΎΠ½Π°ΡΠ°
Background. Currently, there are sufficient data on the favorable role of fast track program on the course of postoperative period. Nevertheless, the role of these protocols being already included in the standards of the surgical treatment of many cancers is not clear to date in oncourology in general and in the prostate cancer (PC).Objective: to determine the effect of fast track program elements for the results of treatment in patients after radical prostatectomy.Materials and methods. 86 radical minimally invasive (laparoscopic or endoscopic extraperitoneal) prostatectomies were performed for prostate cancer in the period from May 2015 to February 2016 in the Oncological Research Institute named after N.N. Petrov. Patients were divided into 2 groups: in patients of the 1st (n = 44) group included those with traditional surgical management fast track elements were not used at all or were used partly; in the 2nd group (n = 42) these elements were used in a whole volume. We have assessed an influence of fast track elements on the frequency of perioperative and early postoperative complications, operative time, duration of the hospitalization and duration of the stay in intensive care unit, frequency of the repeated surgical interventions, and frequency of the repeated hospitalizations within 30 days of the postoperative period.Results. The presence and the absence of preoperative preparation did not affect an incidence of intraoperative complications. Intraoperative blood loss did not lead to blood transfusions. There were no significant differences in the incidence of 30-day complications between groups. WhenΒ evaluating postoperative parameters there was difference between 1st and 2nd groups in the pelvis drainage (3.3 and 0.9 days, respectively, p = 0.002), an average duration of catheterization (11.2 and 5.2 days, respectively, p = 0.0003) and duration of hospitalization (15.1 and 6.5 days, respectively, p = 0.0008).Conclusion. Application of fast track program of perioperative management of patients with prostate cancer does not affect the frequency of intraand postoperative complications, but economically it is potentially more feasible, primarily by reducing the term of the patient stay in hospital.ΠΠ²Π΅Π΄Π΅Π½ΠΈΠ΅. Π Π½Π°ΡΡΠΎΡΡΠ΅Π΅ Π²ΡΠ΅ΠΌΡ ΡΡΡΠ΅ΡΡΠ²ΡΠ΅Ρ Π΄ΠΎΡΡΠ°ΡΠΎΡΠ½ΠΎ Π΄Π°Π½Π½ΡΡ
ΠΎ Π±Π»Π°Π³ΠΎΠΏΡΠΈΡΡΠ½ΠΎΠΉ ΡΠΎΠ»ΠΈ ΠΏΡΠΎΠ³ΡΠ°ΠΌΠΌΡ ΡΠ°Π½Π½Π΅Π³ΠΎ Π²ΠΎΡΡΡΠ°Π½ΠΎΠ²Π»Π΅Π½ΠΈΡ (fast track) Π½Π° ΡΠ΅ΡΠ΅Π½ΠΈΠ΅ ΠΏΠΎΡΠ»Π΅ΠΎΠΏΠ΅ΡΠ°ΡΠΈΠΎΠ½Π½ΠΎΠ³ΠΎ ΠΏΠ΅ΡΠΈΠΎΠ΄Π°. Π’Π΅ΠΌ Π½Π΅ ΠΌΠ΅Π½Π΅Π΅ ΡΠΎΠ»Ρ ΡΡΠΈΡ
ΠΏΡΠΎΡΠΎΠΊΠΎΠ»ΠΎΠ², ΡΠΆΠ΅ Π²ΠΊΠ»ΡΡΠ΅Π½Π½ΡΡ
Π² ΡΡΠ°Π½Π΄Π°ΡΡΡ ΠΏΡΠΈ Ρ
ΠΈΡΡΡΠ³ΠΈΡΠ΅ΡΠΊΠΎΠΌ Π»Π΅ΡΠ΅Π½ΠΈΠΈ ΠΌΠ½ΠΎΠ³ΠΈΡ
ΠΎΠ½ΠΊΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ
Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΠΉ, Π½Π° ΡΠ΅Π³ΠΎΠ΄Π½ΡΡΠ½ΠΈΠΉ Π΄Π΅Π½Ρ Π² ΠΎΠ½ΠΊΠΎΡΡΠΎΠ»ΠΎΠ³ΠΈΠΈ Π² ΡΠ΅Π»ΠΎΠΌ ΠΈ ΠΏΡΠΈ ΡΠ°ΠΊΠ΅ ΠΏΡΠ΅Π΄ΡΡΠ°ΡΠ΅Π»ΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ (Π ΠΠ) Π² ΡΠ°ΡΡΠ½ΠΎΡΡΠΈ Π½Π΅ ΡΡΠ½Π°.Π¦Π΅Π»Ρ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ β ΠΎΠΏΡΠ΅Π΄Π΅Π»ΠΈΡΡ Π²Π»ΠΈΡΠ½ΠΈΠ΅ ΡΠ»Π΅ΠΌΠ΅Π½ΡΠΎΠ² ΠΏΡΠΎΠ³ΡΠ°ΠΌΠΌΡ fast track Π½Π° ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΡ Π»Π΅ΡΠ΅Π½ΠΈΡ Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² ΠΏΠΎΡΠ»Π΅ ΡΠ°Π΄ΠΈΠΊΠ°Π»ΡΠ½ΠΎΠΉ ΠΏΡΠΎΡΡΠ°ΡΡΠΊΡΠΎΠΌΠΈΠΈ.ΠΠ°ΡΠ΅ΡΠΈΠ°Π»Ρ ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ. Π ΠΏΠ΅ΡΠΈΠΎΠ΄ Ρ ΠΌΠ°Ρ 2015 Π³. ΠΏΠΎ ΡΠ΅Π²ΡΠ°Π»Ρ 2016 Π³. Π² ΠΠΠ ΠΎΠ½ΠΊΠΎΠ»ΠΎΠ³ΠΈΠΈ ΠΈΠΌ. Π.Π. ΠΠ΅ΡΡΠΎΠ²Π° ΠΏΡΠΎΠ²Π΅Π΄Π΅Π½ΠΎ 86 ΡΠ°Π΄ΠΈΠΊΠ°Π»ΡΠ½ΡΡ
ΠΌΠΈΠ½ΠΈΠΌΠ°Π»ΡΠ½ΠΎ ΠΈΠ½Π²Π°Π·ΠΈΠ²Π½ΡΡ
(Π»Π°ΠΏΠ°ΡΠΎΡΠΊΠΎΠΏΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΈΠ»ΠΈ Π²Π½Π΅Π±ΡΡΡΠΈΠ½Π½ΡΡ
ΡΠ½Π΄ΠΎΡΠΊΠΎΠΏΠΈΡΠ΅ΡΠΊΠΈΡ
) ΠΏΡΠΎΡΡΠ°ΡΡΠΊΡΠΎΠΌΠΈΠΉ ΠΏΠΎ ΠΏΠΎΠ²ΠΎΠ΄Ρ Π ΠΠ. ΠΠΎΠ»ΡΠ½ΡΠ΅ Π±ΡΠ»ΠΈ ΡΠ°Π·Π΄Π΅Π»Π΅Π½Ρ Π½Π° 2 Π³ΡΡΠΏΠΏΡ: Π² 1-ΠΉ Π³ΡΡΠΏΠΏΠ΅ (n = 44) ΡΡΠ°Π΄ΠΈΡΠΈΠΎΠ½Π½ΠΎΠ³ΠΎ Ρ
ΠΈΡΡΡΠ³ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ Π²Π΅Π΄Π΅Π½ΠΈΡ ΡΠ»Π΅ΠΌΠ΅Π½ΡΡ fast track Π½Π΅ ΠΏΡΠΈΠΌΠ΅Π½ΡΠ»ΠΈ ΡΠΎΠ²ΡΠ΅ΠΌ ΠΈΠ»ΠΈ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π»ΠΈ ΡΠ°ΡΡΠΈΡΠ½ΠΎ; Π²ΠΎ 2-ΠΉ (n = 42) β Π² ΠΏΠΎΠ»Π½ΠΎΠΌ ΠΎΠ±ΡΠ΅ΠΌΠ΅. ΠΡΠ΅Π½ΠΈΠ²Π°Π»ΠΈ Π²Π»ΠΈΡΠ½ΠΈΠ΅ Π²ΡΠΏΠΎΠ»Π½Π΅Π½ΠΈΡ ΠΏΠΎΠ»ΠΎΠΆΠ΅Π½ΠΈΠΉ fast track Π½Π° ΡΠ°ΡΡΠΎΡΡ ΠΈΠ½ΡΡΠ°ΠΎΠΏΠ΅ΡΠ°ΡΠΈΠΎΠ½Π½ΡΡ
ΠΈ ΡΠ°Π½Π½ΠΈΡ
ΠΏΠΎΡΠ»Π΅ΠΎΠΏΠ΅ΡΠ°ΡΠΈΠΎΠ½Π½ΡΡ
ΠΎΡΠ»ΠΎΠΆΠ½Π΅Π½ΠΈΠΉ, Π΄Π»ΠΈΡΠ΅Π»ΡΠ½ΠΎΡΡΡ ΠΎΠΏΠ΅ΡΠ°ΡΠΈΠΈ, ΡΡΠΎΠΊΠΈ Π³ΠΎΡΠΏΠΈΡΠ°Π»ΠΈΠ·Π°ΡΠΈΠΈ ΠΈ Π½Π°Ρ
ΠΎΠΆΠ΄Π΅Π½ΠΈΡ Π² ΠΎΡΠ΄Π΅Π»Π΅- Π½ΠΈΠΈ ΡΠ΅Π°Π½ΠΈΠΌΠ°ΡΠΈΠΈ ΠΈ ΠΈΠ½ΡΠ΅Π½ΡΠΈΠ²Π½ΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ, ΡΠ°ΡΡΠΎΡΡ ΠΏΠΎΠ²ΡΠΎΡΠ½ΡΡ
Ρ
ΠΈΡΡΡΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ
Π²ΠΌΠ΅ΡΠ°ΡΠ΅Π»ΡΡΡΠ², Π° ΡΠ°ΠΊΠΆΠ΅ ΠΏΠΎΠ²ΡΠΎΡΠ½ΡΡ
Π³ΠΎΡΠΏΠΈΡΠ°Π»ΠΈΠ·Π°ΡΠΈΠΉ Π² ΡΠ΅ΡΠ΅Π½ΠΈΠ΅ 30 Π΄Π½Π΅ΠΉ ΠΏΠΎΡΠ»Π΅ΠΎΠΏΠ΅ΡΠ°ΡΠΈΠΎΠ½Π½ΠΎΠ³ΠΎ ΠΏΠ΅ΡΠΈΠΎΠ΄Π°.Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ. ΠΠ°Π»ΠΈΡΠΈΠ΅ ΠΈ ΠΎΡΡΡΡΡΡΠ²ΠΈΠ΅ ΠΏΡΠ΅Π΄ΠΎΠΏΠ΅ΡΠ°ΡΠΈΠΎΠ½Π½ΠΎΠΉ ΠΏΠΎΠ΄Π³ΠΎΡΠΎΠ²ΠΊΠΈ Π½Π΅ ΠΏΠΎΠ²Π»ΠΈΡΠ»ΠΈ Π½Π° ΡΠ°ΡΡΠΎΡΡ ΡΠ°Π·Π²ΠΈΡΠΈΡ ΠΈΠ½ΡΡΠ°ΠΎΠΏΠ΅ΡΠ°ΡΠΈΠΎΠ½Π½ΡΡ
ΠΎΡΠ»ΠΎΠΆΠ½Π΅Π½ΠΈΠΉ. ΠΠ½ΡΡΠ°ΠΎΠΏΠ΅ΡΠ°ΡΠΈΠΎΠ½Π½Π°Ρ ΠΊΡΠΎΠ²ΠΎΠΏΠΎΡΠ΅ΡΡ Π½Π΅ ΠΏΡΠΈΠ²Π΅Π»Π° ΠΊ Π½Π΅ΠΎΠ±Ρ
ΠΎΠ΄ΠΈΠΌΠΎΡΡΠΈ Π²ΡΠΏΠΎΠ»Π½Π΅Π½ΠΈΡ Π³Π΅ΠΌΠΎΡΡΠ°Π½ΡΡΡΠ·ΠΈΠΉ. ΠΠΎΡΡΠΎΠ²Π΅ΡΠ½ΡΡ
ΡΠ°Π·Π»ΠΈΡΠΈΠΉ Π² ΡΠ°ΡΡΠΎΡΠ΅ ΡΠ°Π·Π²ΠΈΡΠΈΡ 30-Π΄Π½Π΅Π²Π½ΡΡ
ΠΎΡΠ»ΠΎΠΆΠ½Π΅Π½ΠΈΠΉ ΠΌΠ΅ΠΆΠ΄Ρ Π³ΡΡΠΏΠΏΠ°ΠΌΠΈ Π½Π΅ Π½Π°Π±Π»ΡΠ΄Π°Π»ΠΈ. ΠΡΠΈ ΠΎΡΠ΅Π½ΠΊΠ΅ ΠΏΠΎΡΠ»Π΅ΠΎΠΏΠ΅ΡΠ°ΡΠΈΠΎΠ½Π½ΡΡ
ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»Π΅ΠΉ ΠΎΡΠΌΠ΅ΡΠ΅Π½Π° ΡΠ°Π·Π½ΠΈΡΠ° ΠΌΠ΅ΠΆΠ΄Ρ 1-ΠΉ ΠΈ 2-ΠΉ Π³ΡΡΠΏΠΏΠ°ΠΌΠΈ Π² Π΄Π»ΠΈΡΠ΅Π»ΡΠ½ΠΎΡΡΠΈ Π΄ΡΠ΅Π½ΠΈΡΠΎΠ²Π°Π½ΠΈΡ ΡΠ°Π·Π° (3,3 ΠΈ 0,9 ΡΡΡ ΡΠΎΠΎΡΠ²Π΅ΡΡΡΠ²Π΅Π½Π½ΠΎ, p = 0,002), ΡΡΠ΅Π΄Π½Π΅ΠΉ Π΄Π»ΠΈ- ΡΠ΅Π»ΡΠ½ΠΎΡΡΠΈ ΠΊΠ°ΡΠ΅ΡΠ΅ΡΠΈΠ·Π°ΡΠΈΠΈ (11,2 ΠΈ 5,2 ΡΡΡ ΡΠΎΠΎΡΠ²Π΅ΡΡΡΠ²Π΅Π½Π½ΠΎ, p = 0,0003) ΠΈ Π΄Π»ΠΈΡΠ΅Π»ΡΠ½ΠΎΡΡΠΈ Π³ΠΎΡΠΏΠΈΡΠ°Π»ΠΈΠ·Π°ΡΠΈΠΈ (15,1 ΠΈ 6,5 ΡΡΡ ΡΠΎΠΎΡΠ²Π΅ΡΡΡΠ²Π΅Π½Π½ΠΎ, p = 0,0008).ΠΠ°ΠΊΠ»ΡΡΠ΅Π½ΠΈΠ΅. ΠΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΠ΅ ΠΏΡΠΈΠ½ΡΠΈΠΏΠΎΠ² ΡΡΠΊΠΎΡΠ΅Π½Π½ΠΎΠΉ ΠΏΡΠΎΠ³ΡΠ°ΠΌΠΌΡ ΠΏΠ΅ΡΠΈΠΎΠΏΠ΅ΡΠ°ΡΠΈΠΎΠ½Π½ΠΎΠ³ΠΎ Π²Π΅Π΄Π΅Π½ΠΈΡ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² (fast track) ΠΏΡΠΈ Π»Π΅ΡΠ΅Π½ΠΈΠΈ Π±ΠΎΠ»ΡΠ½ΡΡ
Π ΠΠ Π½Π΅ Π²Π»ΠΈΡΠ΅Ρ Π½Π° ΡΠ°ΡΡΠΎΡΡ ΠΈΠ½ΡΡΠ°- ΠΈ ΠΏΠΎΡΠ»Π΅ΠΎΠΏΠ΅ΡΠ°ΡΠΈΠΎΠ½Π½ΡΡ
ΠΎΡΠ»ΠΎΠΆΠ½Π΅Π½ΠΈΠΉ, ΠΎΠ΄Π½Π°ΠΊΠΎ ΠΏΠΎΡΠ΅Π½ΡΠΈΠ°Π»ΡΠ½ΠΎ ΡΠΊΠΎΠ½ΠΎΠΌΠΈΡΠ΅ΡΠΊΠΈ Π±ΠΎΠ»Π΅Π΅ ΡΠ΅Π»Π΅ΡΠΎΠΎΠ±ΡΠ°Π·Π½ΠΎ ΠΏΡΠ΅ΠΆΠ΄Π΅ Π²ΡΠ΅Π³ΠΎ Π·Π° ΡΡΠ΅Ρ ΡΠΌΠ΅Π½ΡΡΠ΅Π½ΠΈΡ ΡΡΠΎΠΊΠ° Π½Π°Ρ
ΠΎΠΆΠ΄Π΅Π½ΠΈΡ Π±ΠΎΠ»ΡΠ½ΠΎΠ³ΠΎ Π² ΡΡΠ°ΡΠΈΠΎΠ½Π°ΡΠ΅
ΠΡΠ²Π΅Ρ Π½Π° ΡΠ΅ΡΠ΅Π½Π·ΠΈΡ ΠΊ ΡΡΠ°ΡΡΠ΅ "Π Π°Π½Π½Π΅Π΅ ΡΠ΄Π°Π»Π΅Π½ΠΈΠ΅ ΡΡΠ΅ΡΡΠ°Π»ΡΠ½ΠΎΠ³ΠΎ ΠΊΠ°ΡΠ΅ΡΠ΅ΡΠ° ΠΏΠΎΡΠ»Π΅ ΡΠΊΡΡΡΠ°ΠΏΠ΅ΡΠΈΡΠΎΠ½Π΅ΠΎΡΠΊΠΎΠΏΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΠ°Π΄ΠΈΠΊΠ°Π»ΡΠ½ΠΎΠΉ ΠΏΡΠΎΡΡΠ°ΡΡΠΊΡΠΎΠΌΠΈΠΈ"
.Β Β ΠΠ»ΡΠ±ΠΎΠΊΠΎΡΠ²Π°ΠΆΠ°Π΅ΠΌΡΠ΅ ΠΊΠΎΠ»Π»Π΅Π³ΠΈ!Β Β Β Β Β Β Β Β Β Β Β Β ΠΡ ΡΠΎΠ²Π΅ΡΡΠ΅Π½Π½ΠΎ ΡΠΎΠ³Π»Π°ΡΠ½Ρ, ΡΡΠΎ ΠΎΡΡΡΡΡΡΠ²ΠΈΠ΅ ΡΡΠ°Π²Π½ΠΈΡΠ΅Π»ΡΠ½ΠΎΠΉ ΠΊΠΎΠ³ΠΎΡΡΡ β Π½Π°ΠΈΠ±ΠΎΠ»Π΅Π΅ ΡΡΡΠ΅ΡΡΠ²Π΅Π½Π½ΡΠΉ Π½Π΅Π΄ΠΎΡΡΠ°ΡΠΎΠΊ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ, ΠΎΠ΄Π½Π°ΠΊΠΎ ΡΡΠ°Π²Π½Π΅Π½ΠΈΠ΅ Ρ Π³ΡΡΠΏΠΏΠΎΠΉ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ Π±ΠΎΠ»Π΅Π΅ ΠΏΠΎΠ·Π΄Π½ΠΈΠΌ ΡΠ΄Π°Π»Π΅Π½ΠΈΠ΅ΠΌ ΠΊΠ°ΡΠ΅ΡΠ΅ΡΠ° Π½Π΅ ΠΏΡΠΎΠ²Π΅Π΄Π΅Π½ΠΎ ΠΏΠΎ ΠΏΡΠΈΡΠΈΠ½Π΅ ΡΡΡΠ΅ΡΡΠ²Π΅Π½Π½ΠΎΠΉ Π½Π΅ΠΎΠ΄Π½ΠΎΡΠΎΠ΄Π½ΠΎΡΡΠΈ Π³ΡΡΠΏΠΏ ΠΏΠΎ ΠΏΡΠΈΡΠΈΠ½Π΅ ΡΠ°Π·Π½ΠΎΠΉ ΡΠ΅Ρ
Π½ΠΈΠΊΠΈ (Π² ΠΏΠΎΡΠ»Π΅Π΄Π½Π΅ΠΌ ΡΠ»ΡΡΠ°Π΅ Π±ΠΎΠ»ΡΠ½ΡΠ΅ ΠΎΠΏΠ΅ΡΠΈΡΠΎΠ²Π°Π»ΠΈΡΡ Π² ΠΎΡΠ½ΠΎΠ²Π½ΠΎΠΌ ΡΡΠ΅Π·Π±ΡΡΡΠΈΠ½Π½ΠΎ) ΠΈ ΡΠ°Π·Π½ΡΠΌ ΠΎΠ½ΠΊΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΠΌ ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»ΡΠΌ (Π±ΠΎΠ»Π΅Π΅ Π²ΡΡΠΎΠΊΠ°Ρ ΡΡΠ°Π΄ΠΈΡ, Π½ΠΈΠ·ΠΊΠ°Ρ Π΄ΠΈΡΡΠ΅ΡΠ΅Π½ΡΠΈΡΠΎΠ²ΠΊΠ° ΠΈ Ρ.ΠΏ.).Β Β Β Β Β Β Β Β Β Β ΠΠ΅ΠΉΡΡΠ²ΠΈΡΠ΅Π»ΡΠ½ΠΎ,Β ΠΏΠ°ΡΠΎΠΌΠΎΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΈ ΡΠ°Π½Π½ΠΈΠ΅ ΠΎΠ½ΠΊΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΡ Π»Π΅ΡΠ΅Π½ΠΈΡ Π½Π΅ ΡΠ²Π»ΡΠ»ΠΈΡΡ ΠΎΡΠ½ΠΎΠ²Π½ΡΠΌΠΈ ΠΈ ΠΏΡΠΈΠ²Π΅Π΄Π΅Π½Ρ ΠΎΠ½ΠΈ Π² ΡΡΠ°ΡΡΠ΅ Π΄Π»Ρ ΠΎΡΠΎΠ±ΡΠ°ΠΆΠ΅Π½ΠΈΡ ΡΠΎΠ³ΠΎ, ΡΡΠΎ Π½Π΅ΠΊΠΎΡΠΎΡΡΠ΅ ΡΠ΅Ρ
Π½ΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΌΠΎΠΌΠ΅Π½ΡΡ (Π½Π°ΠΏΡΠΈΠΌΠ΅Ρ, ΡΠΎΡ
ΡΠ°Π½Π΅Π½ΠΈΠ΅ ΡΠ΅ΠΉΠΊΠΈ ΠΌΠΎΡΠ΅Π²ΠΎΠ³ΠΎ ΠΏΡΠ·ΡΡΡ, Π½Π΅ΡΠ²ΠΎΡΠ±Π΅ΡΠ΅ΠΆΠ΅Π½ΠΈΠ΅ ΠΈΒ ΠΏΡΠΎΡΠ΅Π΅) ΠΌΠΎΠ³ΡΡ ΠΎΠΊΠ°Π·Π°ΡΡ Π²Π»ΠΈΡΠ½ΠΈΠ΅ Π½Π° ΡΡΠ½ΠΊΡΠΈΠΎΠ½Π°Π»ΡΠ½ΡΠ΅ (Π² ΡΠΎΠΌ ΡΠΈΡΠ»Π΅ ΡΡΠ½ΠΊΡΠΈΡ Π²Π΅Π·ΠΈΠΊΠΎΡΡΠ΅ΡΡΠ°Π»ΡΠ½ΠΎΠ³ΠΎ Π°Π½Π°ΡΡΠΎΠΌΠΎΠ·Π° ΠΏΠΎΡΠ»Π΅ ΡΠ΄Π°Π»Π΅Π½ΠΈΡ ΡΡΠ΅ΡΡΠ°Π»ΡΠ½ΠΎΠ³ΠΎ ΠΊΠ°ΡΠ΅ΡΠ΅ΡΠ°) ΠΈ ΠΎΠ½ΠΊΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΡ (ΡΠ°ΡΠΏΡΠΎΡΡΡΠ°Π½Π΅Π½Π½ΠΎΡΡΡ, ΡΠΎΡΡΠΎΡΠ½ΠΈΠ΅ Ρ
ΠΈΡΡΡΠ³ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΠΊΡΠ°Ρ, ΠΈ Ρ.ΠΏ.).Β Β Β Β Β Β Β Β ΠΠ°ΡΠ°ΡΠ΅Π»ΡΠ½ΠΎ ΠΏΠΎΡΠ»Π΅ΠΎΠΏΠ΅ΡΠ°ΡΠΈΠΎΠ½Π½ΡΡ
ΠΎΡΠ»ΠΎΠΆΠ½Π΅Π½ΠΈΠΉ, ΠΏΠΎΡΠ΅Π½ΡΠΈΠ°Π»ΡΠ½ΠΎ ΡΠ²ΡΠ·Π°Π½Π½ΡΠ΅ Ρ ΡΠ°Π½Π½ΠΈΠΌ ΡΠ΄Π°Π»Π΅Π½ΠΈΠ΅ΠΌ Π£Π ΠΎΡΠΌΠ΅ΡΠ΅Π½Ρ Ρ 5 ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² (17,9%), ΡΡΠΎ ΡΠΎΠΎΡΠ²Π΅ΡΡΡΠ²ΡΠ΅Ρ ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΠ°ΠΌ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΉΒ ECaRemAΒ (11%) ΠΈΒ RiprecaΒ (13,9%)
Π Π°Π½Π½Π΅Π΅ ΡΠ΄Π°Π»Π΅Π½ΠΈΠ΅ ΡΡΠ΅ΡΡΠ°Π»ΡΠ½ΠΎΠ³ΠΎ ΠΊΠ°ΡΠ΅ΡΠ΅ΡΠ° ΠΏΠΎΡΠ»Π΅ ΡΠΊΡΡΡΠ°ΠΏΠ΅ΡΠΈΡΠΎΠ½Π΅ΠΎΡΠΊΠΎΠΏΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΠ°Π΄ΠΈΠΊΠ°Π»ΡΠ½ΠΎΠΉ ΠΏΡΠΎΡΡΠ°ΡΡΠΊΡΠΎΠΌΠΈΠΈ
Background. Extraperitoneal radical prostatectomy (RP) in patients with prostate cancer is useful when there are no oncological indications to lymph node dissection (e.g. in low and intermediate-low risk of the disease), and allows to perform precise anastomosis and facilitates the early postoperative period. However, even minimally invasive approach does not avoid such factors as a urinary catheter that may disturb patients.Objective. We assessed the possibility to remove the urinary catheter as early as possible.Materials and methods. 28 patients with low (n = 22) and low-intermediate (n = 6) prostate cancer risk (according to NCCN (National Comprehensive Cancer Network) criteria) underwent an extraperitoneal laparoscopic RP from March 2017 to November 2018. All operations were performed by the same surgeon (A. Nosov). The inclusion criteria were the following: localized prostate cancer, prostate specific antigen (PSA) <10 ng/ml, ISUP group 1β2, life expectancy of more than 10 years and preoperative patientβs counseling (awareness about early catheter removal and discharge). All patients were continent before surgery. During surgery, the prostate and seminal vesicles were removed extraperitoneally without peritoneal cavity opening and conversion. Bladder neck sparing was performed in all cases but nerve-vascular bundles were spared according to indication (preoperative International Index of Erectile Function (IIEF), oncological reasons). Vesicourethral anastomosis was performed by two V-Loc circular sutures. No drainage tubes were inserted to control bleeding/urinary leakage. A urinary catheter Foley 20 Fr was inserted into the bladder after anastomosis completion. No other urinary drainage (suprapubic tubes, etc) was used. Anastomosis resistance and completeness were checked at the end of surgery by filling the bladder with 150 ml of saline through the catheter. Except for cases with macroscopic hematuria, urinary catheters were removed on the 1st postoperative dayβs morning (<24 hours) with an active followup (daily voiding assessment, pelvic ultrasound and postvoided residual volume assessment) on Day 1. Immediately after the catheter removal, alpha-blockers (for urination alleviation) and PDE-5 inhibitors (in patients with neurovascular sparing) were prescribed. All patients were available for a 3-month follow-up. During the follow-up, a monthly combined assessment was performed, including IPSS, QoL, PSA analysis, pelvic ultrasound and urofloumetry.Results. The average patientβs age was 63 years (52β71 years). The median preoperative PSA level was 7.6 ng/ml. The intraoperative technique was unremarkable with no blood transfusion or conversion. All early postoperative complications were classified as minor β grade I, II and IIIa in 2 (7.2 %), 5 (17.8 %) and 1 (3.6 %) patients, respectively. Related to the early catheter removal complications included 1 (3.6 %) patient with urinary leakage (resolved by repeated prolonged urinary catheter insertion) and 4 (14.3 %) with urinary obstruction β resolved by single catheterization (n = 2), percutaneous suprapubic cystostomy (n = 2). No major complications were noticed during the follow-up. Totally, 22 (78.6 %) patients were discharged on the next day after the catheter removal β on the 2nd postoperative day. All discharged patients did not need readmission during the follow-up. Remained 6 (21.4 %) patients stayed at the hospital for 5β18 days. The pathological investigation showed upgrading in 9 (32.1 %) patients with low risk and in 1 (3.6 %) patient with low-intermediate risk. Upstaging to locally advanced forms was noticed in 6 (21.4 %) patients. All patients had the PSA level of <0.2 ng/ml 30β90 days after surgery. Postoperative assessment showed improvement in urinary function and erectile function sparing in selected patients, with no compromising functional results due to the early catheter removal.Conclusion. Despite the common widespread of minimally invasive RP, there is no consensus on the terms of a urinary catheter removal. According to our data, we suggested it might be of some benefit to remove a urinary catheter early in selected and well-informed patients. A thorough vesicourethral anastomosis pursuance, nerve-sparing, bladder neck sparing and Retzius sparing procedure, intraand postoperative assessment is necessary in all cases.ΠΠ²Π΅Π΄Π΅Π½ΠΈΠ΅. ΠΠΊΡΡΡΠ°ΠΏΠ΅ΡΠΈΡΠΎΠ½Π΅Π°Π»ΡΠ½Π°Ρ ΡΠ°Π΄ΠΈΠΊΠ°Π»ΡΠ½Π°Ρ ΠΏΡΠΎΡΡΠ°ΡΡΠΊΡΠΎΠΌΠΈΡ (Π ΠΠ) Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ ΡΠ°ΠΊΠΎΠΌ ΠΏΡΠ΅Π΄ΡΡΠ°ΡΠ΅Π»ΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ ΠΈΡΠΏΠΎΠ»ΡΠ·ΡΠ΅ΡΡΡ ΠΏΡΠΈ ΠΎΡΡΡΡΡΡΠ²ΠΈΠΈ ΠΏΠΎΠΊΠ°Π·Π°Π½ΠΈΠΉ Π΄Π»Ρ Π²ΡΠΏΠΎΠ»Π½Π΅Π½ΠΈΡ ΡΠ°Π·ΠΎΠ²ΠΎΠΉ Π»ΠΈΠΌΡΠ°Π΄Π΅Π½ΡΠΊΡΠΎΠΌΠΈΠΈ, Ρ. Π΅. ΠΏΡΠΈ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΠΈ Π½ΠΈΠ·ΠΊΠΎΠ³ΠΎ ΠΈ ΠΏΡΠΎΠΌΠ΅ΠΆΡΡΠΎΡΠ½ΠΎΠ½ΠΈΠ·ΠΊΠΎΠ³ΠΎ ΡΠΈΡΠΊΠ°. ΠΠΈΠ½ΠΈΠΌΠ°Π»ΡΠ½ΠΎ ΠΈΠ½Π²Π°Π·ΠΈΠ²Π½ΡΠ΅ ΡΠ΅Ρ
Π½ΠΎΠ»ΠΎΠ³ΠΈΠΈ ΠΏΡΠΈ Π΅Π΅ Π²ΡΠΏΠΎΠ»Π½Π΅Π½ΠΈΠΈ ΠΏΠΎΠ·Π²ΠΎΠ»ΡΡΡ ΠΎΡΡΡΠ΅ΡΡΠ²ΠΈΡΡ ΠΏΡΠ΅ΡΠΈΠ·ΠΈΠΎΠ½Π½ΠΎΠ΅ ΡΠΎΡΠΌΠΈΡΠΎΠ²Π°Π½ΠΈΠ΅ Π²Π΅Π·ΠΈΠΊΠΎΡΡΠ΅ΡΡΠ°Π»ΡΠ½ΠΎΠ³ΠΎ Π°Π½Π°ΡΡΠΎΠΌΠΎΠ·Π° ΠΈ Π·Π°ΡΠ°ΡΡΡΡ ΠΎΠ±Π»Π΅Π³ΡΠΈΡΡ ΡΠ΅ΡΠ΅Π½ΠΈΠ΅ ΡΠ°Π½Π½Π΅Π³ΠΎ ΠΏΠΎΡΠ»Π΅ΠΎΠΏΠ΅ΡΠ°ΡΠΈΠΎΠ½Π½ΠΎΠ³ΠΎ ΠΏΠ΅ΡΠΈΠΎΠ΄Π°. Π’Π΅ΠΌ Π½Π΅ ΠΌΠ΅Π½Π΅Π΅ Π΄Π°ΠΆΠ΅ ΠΌΠΈΠ½ΠΈΠΌΠ°Π»ΡΠ½ΠΎ ΠΈΠ½Π²Π°Π·ΠΈΠ²Π½ΡΠΉ ΠΏΠΎΠ΄Ρ
ΠΎΠ΄ Π½Π΅ ΠΏΠΎΠ·Π²ΠΎΠ»ΡΠ΅Ρ ΠΈΠ·Π±Π΅ΠΆΠ°ΡΡ ΡΠ°ΠΊΡΠΎΡΠΎΠ², ΡΡ
ΡΠ΄ΡΠ°ΡΡΠΈΡ
ΠΊΠ°ΡΠ΅ΡΡΠ²ΠΎ ΠΆΠΈΠ·Π½ΠΈ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Π² ΠΏΠΎΡΠ»Π΅ΠΎΠΏΠ΅ΡΠ°ΡΠΈΠΎΠ½Π½ΠΎΠΌ ΠΏΠ΅ΡΠΈΠΎΠ΄Π΅, ΡΠ°ΠΊΠΈΡ
ΠΊΠ°ΠΊ ΡΡΠ΅ΡΡΠ°Π»ΡΠ½ΡΠΉ ΠΊΠ°ΡΠ΅ΡΠ΅Ρ.Π¦Π΅Π»Ρ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ β ΠΎΡΠ΅Π½ΠΊΠ° Π²ΠΎΠ·ΠΌΠΎΠΆΠ½ΠΎΡΡΠΈ ΡΠ΄Π°Π»Π΅Π½ΠΈΡ ΡΡΠ΅ΡΡΠ°Π»ΡΠ½ΠΎΠ³ΠΎ ΠΊΠ°ΡΠ΅ΡΠ΅ΡΠ° Π² ΠΌΠ°ΠΊΡΠΈΠΌΠ°Π»ΡΠ½ΠΎ ΡΠ°Π½Π½ΠΈΠ΅ ΡΡΠΎΠΊΠΈ ΠΏΠΎΡΠ»Π΅ Π²ΡΠΏΠΎΠ»Π½Π΅Π½ΠΈΡ Π ΠΠ.ΠΠ°ΡΠ΅ΡΠΈΠ°Π»Ρ ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ. Π‘ ΠΌΠ°ΡΡΠ° 2017 Π³. ΠΏΠΎ Π½ΠΎΡΠ±ΡΡ 2018 Π³. Π² ΠΠΠΠ¦ ΠΎΠ½ΠΊΠΎΠ»ΠΎΠ³ΠΈΠΈ ΠΈΠΌ. Π. Π. ΠΠ΅ΡΡΠΎΠ²Π° 28 ΠΏΠ°ΡΠΈΠ΅Π½ΡΠ°ΠΌ Ρ ΡΠ°ΠΊΠΎΠΌ ΠΏΡΠ΅Π΄ΡΡΠ°ΡΠ΅Π»ΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ Π½ΠΈΠ·ΠΊΠΎΠ³ΠΎ (n = 22) ΠΈ ΠΏΡΠΎΠΌΠ΅ΠΆΡΡΠΎΡΠ½ΠΎ-Π½ΠΈΠ·ΠΊΠΎΠ³ΠΎ (n = 6) ΡΠΈΡΠΊΠ° (ΡΠΎΠ³Π»Π°ΡΠ½ΠΎ ΠΊΡΠΈΡΠ΅ΡΠΈΡΠΌ NCCN (National Comprehensive Cancer Network)) Π±ΡΠ»Π° ΠΏΡΠΎΠ²Π΅Π΄Π΅Π½Π° ΡΠΊΡΡΡΠ°ΠΏΠ΅ΡΠΈΡΠΎΠ½Π΅Π°Π»ΡΠ½Π°Ρ Π»Π°ΠΏΠ°ΡΠΎΡΠΊΠΎΠΏΠΈΡΠ΅ΡΠΊΠ°Ρ Π ΠΠ. ΠΡΠ΅ ΠΎΠΏΠ΅ΡΠ°ΡΠΈΠΈ Π²ΡΠΏΠΎΠ»Π½Π΅Π½Ρ ΠΎΠ΄Π½ΠΈΠΌ Ρ
ΠΈΡΡΡΠ³ΠΎΠΌ (Π. Π. ΠΠΎΡΠΎΠ²). ΠΡΠΈΡΠ΅ΡΠΈΡΠΌΠΈ Π²ΠΊΠ»ΡΡΠ΅Π½ΠΈΡ Π² ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ ΡΠ²ΠΈΠ»ΠΈΡΡ Π»ΠΎΠΊΠ°Π»ΠΈΠ·ΠΎΠ²Π°Π½Π½ΡΠΉ ΡΠ°ΠΊ ΠΏΡΠ΅Π΄ΡΡΠ°ΡΠ΅Π»ΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ, ΡΡΠΎΠ²Π΅Π½Ρ ΠΏΡΠΎΡΡΠ°ΡΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΡΠΏΠ΅ΡΠΈΡΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ Π°Π½ΡΠΈΠ³Π΅Π½Π° (ΠΠ‘Π) <10 Π½Π³ / ΠΌΠ», ΡΡΠΌΠΌΠ° Π±Π°Π»Π»ΠΎΠ² ΠΏΠΎ ΡΠΊΠ°Π»Π΅ ΠΠ»ΠΈΡΠΎΠ½Π° β€7, ΠΎΠΆΠΈΠ΄Π°Π΅ΠΌΠ°Ρ ΠΏΡΠΎΠ΄ΠΎΠ»ΠΆΠΈΡΠ΅Π»ΡΠ½ΠΎΡΡΡ ΠΆΠΈΠ·Π½ΠΈ Π±ΠΎΠ»Π΅Π΅ 10 Π»Π΅Ρ ΠΈ ΠΏΡΠ΅Π΄ΠΎΠΏΠ΅ΡΠ°ΡΠΈΠΎΠ½Π½ΠΎΠ΅ ΠΊΠΎΠ½ΡΡΠ»ΡΡΠΈΡΠΎΠ²Π°Π½ΠΈΠ΅ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠ° (ΠΎΡΠ²Π΅Π΄ΠΎΠΌΠ»Π΅Π½ΠΈΠ΅ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠ° ΠΎ ΡΠ°Π½Π½Π΅ΠΌ ΡΠ΄Π°Π»Π΅Π½ΠΈΠΈ ΡΡΠ΅ΡΡΠ°Π»ΡΠ½ΠΎΠ³ΠΎ ΠΊΠ°ΡΠ΅ΡΠ΅ΡΠ°). ΠΡΠ΅ ΠΏΠ°ΡΠΈΠ΅Π½ΡΡ ΠΏΠ΅ΡΠ΅Π΄ Π ΠΠ ΠΏΠΎΠ»Π½ΠΎΡΡΡΡ ΡΠ΄Π΅ΡΠΆΠΈΠ²Π°Π»ΠΈ ΠΌΠΎΡΡ. Π Ρ
ΠΎΠ΄Π΅ Π²ΠΌΠ΅ΡΠ°ΡΠ΅Π»ΡΡΡΠ²Π° ΠΏΡΠΎΠ²ΠΎΠ΄ΠΈΠ»ΠΈ ΡΠΊΡΡΡΠ°ΠΏΠ΅ΡΠΈΡΠΎΠ½Π΅Π°Π»ΡΠ½ΠΎΠ΅ ΡΠ΄Π°Π»Π΅Π½ΠΈΠ΅ ΠΏΡΠ΅Π΄ΡΡΠ°ΡΠ΅Π»ΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ, ΡΠ΅ΠΌΠ΅Π½Π½ΡΡ
ΠΏΡΠ·ΡΡΡΠΊΠΎΠ², Π²ΠΎ Π²ΡΠ΅Ρ
ΡΠ»ΡΡΠ°ΡΡ
Π²ΡΠΏΠΎΠ»Π½ΡΠ»ΠΈ ΡΠΎΡ
ΡΠ°Π½Π΅Π½ΠΈΠ΅ ΡΠ΅ΠΉΠΊΠΈ ΠΌΠΎΡΠ΅Π²ΠΎΠ³ΠΎ ΠΏΡΠ·ΡΡΡ ΠΈ ΠΏΡΠΈ Π½Π°Π»ΠΈΡΠΈΠΈ ΠΏΠΎΠΊΠ°Π·Π°Π½ΠΈΠΉ (Π½ΠΎΡΠΌΠ°Π»ΡΠ½Π°Ρ ΠΏΡΠ΅Π΄ΠΎΠΏΠ΅ΡΠ°ΡΠΈΠΎΠ½Π½Π°Ρ ΡΡΠ½ΠΊΡΠΈΡ ΠΏΠΎ ΠΎΡΠ΅Π½ΠΊΠ΅ ΠΎΠΏΡΠΎΡΠ½ΠΈΠΊΠ° ΠΠ΅ΠΆΠ΄ΡΠ½Π°ΡΠΎΠ΄Π½ΠΎΠ³ΠΎ ΠΈΠ½Π΄Π΅ΠΊΡΠ° ΡΡΠ΅ΠΊΡΠΈΠ»ΡΠ½ΠΎΠΉ ΡΡΠ½ΠΊΡΠΈΠΈ (ΠΠΠΠ€-5), ΠΏΠΎΠ΄Ρ
ΠΎΠ΄ΡΡΠΈΠ΅ ΠΎΠ½ΠΊΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΊΡΠΈΡΠ΅ΡΠΈΠΈ) Π½Π΅ΡΠ²ΠΎΡΠ±Π΅ΡΠ΅ΠΆΠ΅Π½ΠΈΠ΅. Π€ΠΎΡΠΌΠΈΡΠΎΠ²Π°Π½ΠΈΠ΅ Π²Π΅Π·ΠΈΠΊΠΎΡΡΠ΅ΡΡΠ°Π»ΡΠ½ΠΎΠ³ΠΎ Π°Π½Π°ΡΡΠΎΠΌΠΎΠ·Π°, ΡΡΠ°ΡΠ΅Π»ΡΠ½ΠΎΡΡΡ ΠΈ ΠΏΡΠ΅ΡΠΈΠ·ΠΈΠΎΠ½Π½ΠΎΡΡΡ ΠΊΠΎΡΠΎΡΠΎΠ³ΠΎ ΡΡΠΈΡΠ°Π»ΠΈΡΡ ΠΊΠ»ΡΡΠ΅Π²ΡΠΌ ΠΌΠΎΠΌΠ΅Π½ΡΠΎΠΌ Π² Π²ΠΎΠ·ΠΌΠΎΠΆΠ½ΠΎΡΡΠΈ ΡΠ°Π½Π½Π΅Π³ΠΎ ΡΠ΄Π°Π»Π΅Π½ΠΈΡ ΡΡΠ΅ΡΡΠ°Π»ΡΠ½ΠΎΠ³ΠΎ ΠΊΠ°ΡΠ΅ΡΠ΅ΡΠ°, ΠΎΡΡΡΠ΅ΡΡΠ²Π»ΡΠ»ΠΈ Ρ ΠΏΠΎΠΌΠΎΡΡΡ ΡΠΈΡΠΊΡΠ»ΡΡΠ½ΠΎΠ³ΠΎ ΡΠ²Π° Π½ΠΈΡΡΠΌΠΈ V-Loc. ΠΠΎΡΠ»Π΅ ΡΠΎΡΠΌΠΈΡΠΎΠ²Π°Π½ΠΈΡ Π°Π½Π°ΡΡΠΎΠΌΠΎΠ·Π° Π΅Π³ΠΎ Π³Π΅ΡΠΌΠ΅ΡΠΈΡΠ½ΠΎΡΡΡ ΠΎΡΠ΅Π½ΠΈΠ²Π°Π»ΠΈ Π²Π²Π΅Π΄Π΅Π½ΠΈΠ΅ΠΌ ΠΏΠΎ ΡΡΡΠ°Π½Π°Π²Π»ΠΈΠ²Π°Π΅ΠΌΠΎΠΌΡ ΡΡΠ΅ΡΡΠ°Π»ΡΠ½ΠΎΠΌΡ ΠΊΠ°ΡΠ΅ΡΠ΅ΡΡ Π€ΠΎΠ»Π΅Ρ β 20 Ch 150 ΠΌΠ» ΡΠΈΠ·ΠΈΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΡΠ°ΡΡΠ²ΠΎΡΠ°. ΠΡΡΠ³ΠΈΠ΅ ΠΌΠΎΡΠ΅Π²ΡΠ΅ / ΡΡΡΠ°Ρ
ΠΎΠ²ΡΠ΅ Π΄ΡΠ΅Π½Π°ΠΆΠΈ Π½Π΅ ΡΡΡΠ°Π½Π°Π²Π»ΠΈΠ²Π°Π»ΠΈ. ΠΠ° ΠΈΡΠΊΠ»ΡΡΠ΅Π½ΠΈΠ΅ΠΌ ΡΠ»ΡΡΠ°Π΅Π² ΠΌΠ°ΠΊΡΠΎΠ³Π΅ΠΌΠ°ΡΡΡΠΈΠΈ ΡΡΠ΅ΡΡΠ°Π»ΡΠ½ΡΠΉ ΠΊΠ°ΡΠ΅ΡΠ΅Ρ ΡΠ΄Π°Π»ΡΠ»ΠΈ Π½Π° 1βΠ΅ ΡΡΡΠΊΠΈ ΠΏΠΎΡΠ»Π΅ΠΎΠΏΠ΅ΡΠ°ΡΠΈΠΎΠ½Π½ΠΎΠ³ΠΎ ΠΏΠ΅ΡΠΈΠΎΠ΄Π° (<24 Ρ) Ρ ΠΏΠΎΡΠ»Π΅Π΄ΡΡΡΠΈΠΌ Π°ΠΊΡΠΈΠ²Π½ΡΠΌ Π½Π°Π±Π»ΡΠ΄Π΅Π½ΠΈΠ΅ΠΌ Π·Π° ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠΌ β ΡΡΠ±ΡΠ΅ΠΊΡΠΈΠ²Π½Π°Ρ ΠΈ ΠΎΠ±ΡΠ΅ΠΊΡΠΈΠ²Π½Π°Ρ ΠΎΡΠ΅Π½ΠΊΠ° ΠΌΠΎΡΠ΅ΠΈΡΠΏΡΡΠΊΠ°Π½ΠΈΡ (Π΄Π½Π΅Π²Π½ΠΈΠΊ ΠΌΠΎΡΠ΅ΠΈΡΠΏΡΡΠΊΠ°Π½ΠΈΠΉ, ΡΠ»ΡΡΡΠ°Π·Π²ΡΠΊΠΎΠ²ΠΎΠ΅ ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΠ΅ ΠΎΡΡΠ°ΡΠΎΡΠ½ΠΎΠΉ ΠΌΠΎΡΠΈ). Π‘ΡΠ°Π·Ρ ΠΏΠΎΡΠ»Π΅ ΡΠ΄Π°Π»Π΅Π½ΠΈΡ ΡΡΠ΅ΡΡΠ°Π»ΡΠ½ΠΎΠ³ΠΎ ΠΊΠ°ΡΠ΅ΡΠ΅ΡΠ° Π½Π°Π·Π½Π°ΡΠ°Π»ΠΈ ΠΈΠ½Π³ΠΈΠ±ΠΈΡΠΎΡΡ Π€ΠΠ-5 (ΠΏΡΠΈ Π²ΡΠΏΠΎΠ»Π½Π΅Π½ΠΈΠΈ Π½Π΅ΡΠ²ΠΎΡΠ±Π΅ΡΠ΅Π³Π°ΡΡΠ΅ΠΉ Π ΠΠ) ΠΈ Ξ±-Π°Π΄ΡΠ΅Π½ΠΎΠ±Π»ΠΎΠΊΠ°ΡΠΎΡΡ. ΠΡΠ΅ ΠΏΠ°ΡΠΈΠ΅Π½ΡΡ Π±ΡΠ»ΠΈ Π΄ΠΎΡΡΡΠΏΠ½Ρ Π΄Π»Ρ 3βΠΌΠ΅ΡΡΡΠ½ΠΎΠ³ΠΎ Π½Π°Π±Π»ΡΠ΄Π΅Π½ΠΈΡ. Π ΡΠ΅ΡΠ΅Π½ΠΈΠ΅ Π½Π°Π±Π»ΡΠ΄Π΅Π½ΠΈΡ ΠΏΡΠΎΠ²ΠΎΠ΄ΠΈΠ»ΠΈ Π΅ΠΆΠ΅ΠΌΠ΅ΡΡΡΠ½ΡΡ ΠΎΡΠ΅Π½ΠΊΡ ΡΠΎΡΡΠΎΡΠ½ΠΈΡ: Π°Π½Π°Π»ΠΈΠ· ΠΎΠΏΡΠΎΡΠ½ΠΈΠΊΠΎΠ² IPSS, QoL, ΡΡΠΎΠ²Π½Ρ ΠΠ‘Π, ΠΎΡΠ΅Π½ΠΊΡ ΠΎΡΡΠ°ΡΠΎΡΠ½ΠΎΠΉ ΠΌΠΎΡΠΈ, ΡΡΠΎΡΠ»ΠΎΡΠΌΠ΅ΡΡΠΈΡ.Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ. Π‘ΡΠ΅Π΄Π½ΠΈΠΉ Π²ΠΎΠ·ΡΠ°ΡΡ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² ΡΠΎΡΡΠ°Π²ΠΈΠ» 63 Π³ΠΎΠ΄Π° (52β71 Π³ΠΎΠ΄). Π‘ΡΠ΅Π΄Π½ΠΈΠΉ ΡΡΠΎΠ²Π΅Π½Ρ ΠΠ‘Π ΠΏΠ΅ΡΠ΅Π΄ ΠΏΡΠΎΠ²Π΅Π΄Π΅Π½ΠΈΠ΅ΠΌ Π ΠΠ β 7,6 Π½Π³ / ΠΌΠ». ΠΠΎ Π²ΡΠ΅ΠΌΡ ΠΎΠΏΠ΅ΡΠ°ΡΠΈΠΈ Π½ΠΈ Ρ ΠΎΠ΄Π½ΠΎΠ³ΠΎ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠ° Π½Π΅ ΠΏΠΎΡΡΠ΅Π±ΠΎΠ²Π°Π»ΠΎΡΡ Π²ΡΠΏΠΎΠ»Π½Π΅Π½ΠΈΡ Π³Π΅ΠΌΠΎΡΡΠ°Π½ΡΡΡΠ·ΠΈΠΈ ΠΈΠ»ΠΈ ΠΊΠΎΠ½Π²Π΅ΡΡΠΈΠΈ. Π ΡΡΠΈΠ½Π½Π°Ρ ΡΠΈΡΡΠΎΠ³ΡΠ°ΡΠΈΡ ΠΏΠ΅ΡΠ΅Π΄ ΡΠ΄Π°Π»Π΅Π½ΠΈΠ΅ΠΌ ΡΡΠ΅ΡΡΠ°Π»ΡΠ½ΠΎΠ³ΠΎ ΠΊΠ°ΡΠ΅ΡΠ΅ΡΠ° Π½Π΅ Π²ΡΠΏΠΎΠ»Π½ΡΠ»Π°ΡΡ. ΠΡΠ΅ ΠΎΡΠ»ΠΎΠΆΠ½Π΅Π½ΠΈΡ ΡΠ°Π½Π½Π΅Π³ΠΎ ΠΏΠΎΡΠ»Π΅ΠΎΠΏΠ΅ΡΠ°ΡΠΈΠΎΠ½Π½ΠΎΠ³ΠΎ ΠΏΠ΅ΡΠΈΠΎΠ΄Π° ΠΎΡΠ½Π΅ΡΠ΅Π½Ρ ΠΊ Π½Π΅Π·Π½Π°ΡΠΈΡΠ΅Π»ΡΠ½ΡΠΌ I, II ΠΈ IIIa ΡΡΠ΅ΠΏΠ΅Π½ΡΠΌ ΡΠΎΠΎΡΠ²Π΅ΡΡΡΠ²Π΅Π½Π½ΠΎ Ρ 2 (7,2 %), 5 (17,8 %) ΠΈ 1 (3,6 %) ΠΏΠ°ΡΠΈΠ΅Π½ΡΠ°. Π‘Π²ΡΠ·Π°Π½Π½ΡΠ΅ Ρ ΡΠ°Π½Π½ΠΈΠΌ ΡΠ΄Π°Π»Π΅Π½ΠΈΠ΅ΠΌ ΡΡΠ΅ΡΡΠ°Π»ΡΠ½ΠΎΠ³ΠΎ ΠΊΠ°ΡΠ΅ΡΠ΅ΡΠ° ΠΎΡΠ»ΠΎΠΆΠ½Π΅Π½ΠΈΡ Π²ΠΊΠ»ΡΡΠ°Π»ΠΈ Π·Π°ΡΠ΅ΠΊ ΠΌΠΎΡΠΈ ΠΈΠ· Π·ΠΎΠ½Ρ Π²Π΅Π·ΠΈΠΊΠΎΡΡΠ΅ΡΡΠ°Π»ΡΠ½ΠΎΠ³ΠΎ Π°Π½Π°ΡΡΠΎΠΌΠΎΠ·Π° (Ρ 1 (3,6 %) ΠΏΠ°ΡΠΈΠ΅Π½ΡΠ° ΡΠ°Π·ΡΠ΅ΡΠ΅Π½ΠΎ ΠΏΠΎΠ²ΡΠΎΡΠ½ΠΎΠΉ ΡΡΡΠ°Π½ΠΎΠ²ΠΊΠΎΠΉ ΠΊΠ°ΡΠ΅ΡΠ΅ΡΠ° ΠΈ ΠΏΡΠΎΠ»ΠΎΠ½Π³ΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠΉ ΠΊΠ°ΡΠ΅ΡΠ΅ΡΠΈΠ·Π°ΡΠΈΠ΅ΠΉ) ΠΈ ΠΎΠ±ΡΡΡΡΠΊΡΠΈΡ ΠΌΠΎΡΠ΅ΠΈΡΠΏΡΡΠΊΠ°Π½ΠΈΡ (Ρ 4 (14,3 %) ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ², ΠΈΠ· Π½ΠΈΡ
2 Π²ΡΠΏΠΎΠ»Π½Π΅Π½Π° ΠΏΠΎΠ²ΡΠΎΡΠ½Π°Ρ ΠΊΠ°ΡΠ΅ΡΠ΅ΡΠΈΠ·Π°ΡΠΈΡ ΠΈ 2 β ΡΡΠΎΠ°ΠΊΠ°ΡΠ½Π°Ρ ΡΠΏΠΈΡΠΈΡΡΠΎΡΡΠΎΠΌΠΈΡ). ΠΠ° ΡΠ»Π΅Π΄ΡΡΡΠΈΠΉ Π΄Π΅Π½Ρ ΠΏΠΎΡΠ»Π΅ ΡΠ΄Π°Π»Π΅Π½ΠΈΡ ΠΊΠ°ΡΠ΅ΡΠ΅ΡΠ° (2βΠΉ ΠΏΠΎΡΠ»Π΅ΠΎΠΏΠ΅ΡΠ°ΡΠΈΠΎΠ½Π½ΡΠΉ Π΄Π΅Π½Ρ) Π±ΡΠ»ΠΈ Π²ΡΠΏΠΈΡΠ°Π½Ρ 22 (78,6 %) ΠΏΠ°ΡΠΈΠ΅Π½ΡΠ°. ΠΠΎΠ²ΡΠΎΡΠ½ΡΡ
Π³ΠΎΡΠΏΠΈΡΠ°Π»ΠΈΠ·Π°ΡΠΈΠΉ Ρ Π±ΠΎΠ»ΡΠ½ΡΡ
ΡΡΠΎΠΉ Π³ΡΡΠΏΠΏΡ Π½Π΅ ΠΏΠΎΡΡΠ΅Π±ΠΎΠ²Π°Π»ΠΎΡΡ. Π£ 6 (21,4 %) ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² ΠΏΡΠΎΠ΄ΠΎΠ»ΠΆΠΈΡΠ΅Π»ΡΠ½ΠΎΡΡΡ Π³ΠΎΡΠΏΠΈΡΠ°Π»ΠΈΠ·Π°ΡΠΈΠΈ ΡΠΎΡΡΠ°Π²ΠΈΠ»Π° 5β18 Π΄Π½Π΅ΠΉ. ΠΡΠ΅Π΄ΠΎΠΏΠ΅ΡΠ°ΡΠΈΠΎΠ½Π½ΠΎΠ΅ Π·Π°Π½ΠΈΠΆΠ΅Π½ΠΈΠ΅ ΡΡΠ΅ΠΏΠ΅Π½ΠΈ Π΄ΠΈΡΡΠ΅ΡΠ΅Π½ΡΠΈΡΠΎΠ²ΠΊΠΈ ΠΎΡΠΌΠ΅ΡΠ΅Π½ΠΎ Ρ 9 (32,1 %) ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² ΠΈΠ· Π³ΡΡΠΏΠΏΡ Π½ΠΈΠ·ΠΊΠΎΠ³ΠΎ ΡΠΈΡΠΊΠ° ΠΈ Ρ 1 (3,6 %) Π±ΠΎΠ»ΡΠ½ΠΎΠ³ΠΎ ΠΈΠ· Π³ΡΡΠΏΠΏΡ ΠΏΡΠΎΠΌΠ΅ΠΆΡΡΠΎΡΠ½ΠΎ-Π½ΠΈΠ·ΠΊΠΎΠ³ΠΎ. Π 6 ΡΠ»ΡΡΠ°ΡΡ
ΠΈΠ·Π½Π°ΡΠ°Π»ΡΠ½ΠΎ Π»ΠΎΠΊΠ°Π»ΠΈΠ·ΠΎΠ²Π°Π½Π½ΡΠΉ ΠΏΡΠΎΡΠ΅ΡΡ ΠΏΠ°ΡΠΎΠΌΠΎΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈ ΠΎΡΠ΅Π½Π΅Π½ ΠΊΠ°ΠΊ ΠΌΠ΅ΡΡΠ½ΠΎ-ΡΠ°ΡΠΏΡΠΎΡΡΡΠ°Π½Π΅Π½Π½ΡΠΉ Ρ ΠΈΠ½Π²Π°Π·ΠΈΠ΅ΠΉ Π² ΡΠ΅ΠΌΠ΅Π½Π½ΡΠ΅ ΠΏΡΠ·ΡΡΡΠΊΠΈ (n = 2) ΠΈΠ»ΠΈ Ρ ΡΠΊΡΡΡΠΎΠΏΡΠΎΡΡΠ°ΡΠΈΡΠ΅ΡΠΊΠΈΠΌ ΡΠ°ΡΠΏΡΠΎΡΡΡΠ°Π½Π΅Π½ΠΈΠ΅ΠΌ (n = 4). ΠΡΠ΅ ΠΏΡΠΎΠΎΠΏΠ΅ΡΠΈΡΠΎΠ²Π°Π½Π½ΡΠ΅ ΠΏΠ°ΡΠΈΠ΅Π½ΡΡ ΠΈΠΌΠ΅Π»ΠΈ ΡΡΠΎΠ²Π΅Π½Ρ ΠΠ‘Π <0,2 Π½Π³ / ΠΌΠ» Π² ΡΠ΅ΡΠ΅Π½ΠΈΠ΅ 90 Π΄Π½Π΅ΠΉ ΠΏΠΎΡΠ»Π΅ ΠΎΠΏΠ΅ΡΠ°ΡΠΈΠΈ. ΠΠΎΡΠ»Π΅ΠΎΠΏΠ΅ΡΠ°ΡΠΈΠΎΠ½Π½Π°Ρ ΠΎΡΠ΅Π½ΠΊΠ° ΠΏΠΎΠΊΠ°Π·Π°Π»Π° ΡΠ»ΡΡΡΠ΅Π½ΠΈΠ΅ ΡΡΠ½ΠΊΡΠΈΠΈ ΠΌΠΎΡΠ΅ΠΈΡΠΏΡΡΠΊΠ°Π½ΠΈΡ ΠΈ Ρ ΠΎΡΠ΄Π΅Π»ΡΠ½ΡΡ
ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² ΡΠΎΡ
ΡΠ°Π½Π΅Π½ΠΈΠ΅ ΡΡΠ΅ΠΊΡΠΈΠ»ΡΠ½ΠΎΠΉ ΡΡΠ½ΠΊΡΠΈΠΈ ΠΏΠΎΡΠ»Π΅ Π²ΡΠΏΠΎΠ»Π½Π΅Π½ΠΈΡ Π ΠΠ Ρ ΠΏΠΎΡΠ»Π΅ΠΎΠΏΠ΅ΡΠ°ΡΠΈΠΎΠ½Π½ΡΠΌ Π²Π΅Π΄Π΅Π½ΠΈΠ΅ΠΌ ΠΏΠΎ ΠΏΡΠ΅Π΄Π»ΠΎΠΆΠ΅Π½Π½ΠΎΠΉ ΠΌΠ΅ΡΠΎΠ΄ΠΈΠΊΠ΅.ΠΠ°ΠΊΠ»ΡΡΠ΅Π½ΠΈΠ΅. ΠΠ΅ΡΠΌΠΎΡΡΡ Π½Π° ΡΠ°Π·Π²ΠΈΡΠΈΠ΅ Ρ
ΠΈΡΡΡΠ³ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΠ΅Ρ
Π½ΠΈΠΊΠΈ ΠΈ ΡΠΈΡΠΎΠΊΠΎΠ΅ ΡΠ°ΡΠΏΡΠΎΡΡΡΠ°Π½Π΅Π½ΠΈΠ΅ ΠΌΠΈΠ½ΠΈΠΌΠ°Π»ΡΠ½ΠΎ ΠΈΠ½Π²Π°Π·ΠΈΠ²Π½ΠΎΠ³ΠΎ ΠΏΠΎΠ΄Ρ
ΠΎΠ΄Π° Π² Ρ
ΠΈΡΡΡΠ³ΠΈΡΠ΅ΡΠΊΠΎΠΌ Π»Π΅ΡΠ΅Π½ΠΈΠΈ ΡΠ°ΠΊΠ° ΠΏΡΠ΅Π΄ΡΡΠ°ΡΠ΅Π»ΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ, Π΅Π΄ΠΈΠ½ΠΎΠ³ΠΎ ΠΌΠ½Π΅Π½ΠΈΡ ΠΎ ΡΡΠΎΠΊΠ°Ρ
ΡΠ΄Π°Π»Π΅Π½ΠΈΡ ΡΡΠ΅ΡΡΠ°Π»ΡΠ½ΠΎΠ³ΠΎ ΠΊΠ°ΡΠ΅ΡΠ΅ΡΠ° Π½Π΅Ρ. ΠΠ°ΡΠΈ ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΡ ΠΏΠΎΠΊΠ°Π·Π°Π»ΠΈ, ΡΡΠΎ ΠΏΡΠΈ Π°Π΄Π΅ΠΊΠ²Π°ΡΠ½ΠΎΠΌ ΡΠΎΡΠΌΠΈΡΠΎΠ²Π°Π½ΠΈΠΈ Π²Π΅Π·ΠΈΠΊΠΎΡΡΠ΅ΡΡΠ°Π»ΡΠ½ΠΎΠ³ΠΎ Π°Π½Π°ΡΡΠΎΠΌΠΎΠ·Π° Ρ ΡΠΎΡ
ΡΠ°Π½Π΅Π½ΠΈΠ΅ΠΌ ΡΠ΅ΠΉΠΊΠΈ ΠΌΠΎΡΠ΅Π²ΠΎΠ³ΠΎ ΠΏΡΠ·ΡΡΡ, ΡΠ΅ΡΡΠΈΠ΅Π²ΠΎΠ³ΠΎ ΠΏΡΠΎΡΡΡΠ°Π½ΡΡΠ²Π°, ΠΏΡΠΈ Π²ΡΠΏΠΎΠ»Π½Π΅Π½ΠΈΠΈ Π½Π΅ΡΠ²ΠΎΡΠ±Π΅ΡΠ΅ΠΆΠ΅Π½ΠΈΡ, ΡΡΠ°ΡΠ΅Π»ΡΠ½ΠΎΠΌ ΠΏΡΠ΅ΡΠΈΠ·ΠΈΠΎΠ½Π½ΠΎΠΌ ΡΠΎΡΠΌΠΈΡΠΎΠ²Π°Π½ΠΈΠΈ Π°Π½Π°ΡΡΠΎΠΌΠΎΠ·Π°, ΠΎΠ±ΡΠ·Π°ΡΠ΅Π»ΡΠ½ΠΎΠΌ ΠΈΠ½ΡΡΠ°ΠΈ ΠΏΠΎΡΠ»Π΅ΠΎΠΏΠ΅ΡΠ°ΡΠΈΠΎΠ½Π½ΠΎΠΌ ΠΊΠΎΠ½ΡΡΠΎΠ»Π΅ ΠΈ Ρ ΠΏΡΠΎΠΈΠ½ΡΠΎΡΠΌΠΈΡΠΎΠ²Π°Π½Π½ΡΡ
ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Π²ΠΎΠ·ΠΌΠΎΠΆΠ½ΠΎ ΡΠ°Π½Π½Π΅Π΅ ΡΠ΄Π°Π»Π΅Π½ΠΈΠ΅ ΠΊΠ°ΡΠ΅ΡΠ΅ΡΠ°
ΠΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΠ΅ ΡΡΡΠ΅ΠΏΡΠΎΠΊΠΈΠ½Π°Π·Ρ ΠΏΡΠΈ ΡΠ²Π΅ΡΠ½ΡΠ²ΡΠ΅ΠΌΡΡ Π³Π΅ΠΌΠΎΡΠΎΡΠ°ΠΊΡΠ΅
Pleural effusion in patients with clotting haemothorax is characterized by high coagulant potential and low fibrinolytic activity. Streptokinase is an effective drug for pharmacological lung decortication in patients with high pleural concentration of plasminogen.Intrapleural administration of streptokinase-activated fresh frozen plasma increased efficacy of conservative therapy and provided better outcome in clotting haemothorax.Π£ Π±ΠΎΠ»ΡΠ½ΡΡ
ΡΠ²Π΅ΡΠ½ΡΠ²ΡΠΈΠΌΡΡ Π³Π΅ΠΌΠΎΡΠΎΡΠ°ΠΊΡΠΎΠΌ (Π‘Π) Π² ΠΏΠ»Π΅Π²ΡΠ°Π»ΡΠ½ΠΎΠΌ ΡΠΊΡΡΡΠ΄Π°ΡΠ΅ ΠΏΡΠΈ ΡΠΎΡ
ΡΠ°Π½Π΅Π½Π½ΠΎΠΌ ΠΊΠΎΠ°Π³ΡΠ»ΡΡΠΈΠΎΠ½Π½ΠΎΠΌ ΠΏΠΎΡΠ΅Π½ΡΠΈΠ°Π»Π΅ Π·Π½Π°ΡΠΈΡΠ΅Π»ΡΠ½ΠΎ ΡΠ³Π½Π΅ΡΠ΅Π½ ΡΠΈΠ±ΡΠΈΠ½ΠΎΠ»ΠΈΠ·, ΡΡΠΎ ΡΠΏΠΎΡΠΎΠ±ΡΡΠ²ΡΠ΅Ρ ΡΠΈΠ±ΡΠΈΠ½ΠΎΠΎΠ±ΡΠ°Π·ΠΎΠ²Π°Π½ΠΈΡ Π² ΠΏΠ»Π΅Π²ΡΠ°Π»ΡΠ½ΠΎΠΉ ΠΏΠΎΠ»ΠΎΡΡΠΈ. ΠΠ½ΡΡΡΠΈΠΏΠ»Π΅Π²ΡΠ°Π»ΡΠ½ΠΎΠ΅ Π²Π²Π΅Π΄Π΅Π½ΠΈΠ΅ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠΎΠ² ΡΡΡΠ΅ΠΏΡΠΎΠΊΠΈΠ½Π°Π·Ρ ΡΠ²Π»ΡΠ΅ΡΡΡ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΡΠΌ ΡΠΏΠΎΡΠΎΠ±ΠΎΠΌ ΠΌΠ΅Π΄ΠΈΠΊΠ°ΠΌΠ΅Π½ΡΠΎΠ·Π½ΠΎΠΉ Π΄Π΅ΠΊΠΎΡΡΠΈΠΊΠ°ΡΠΈΠΈ Π»Π΅Π³ΠΊΠΎΠ³ΠΎ Ρ Π±ΠΎΠ»ΡΠ½ΡΡ
ΡΠ²Π΅ΡΠ½ΡΠ²ΡΠΈΠΌΡΡ Π³Π΅ΠΌΠΎΡΠΎΡΠ°ΠΊΡΠΎΠΌ Ρ Π²ΡΡΠΎΠΊΠΈΠΌ ΡΠΎΠ΄Π΅ΡΠΆΠ°Π½ΠΈΠ΅ΠΌ ΠΏΠ»Π°Π·ΠΌΠΈΠ½ΠΎΠ³Π΅Π½Π° Π² ΠΏΠ»Π΅Π²ΡΠ°Π»ΡΠ½ΠΎΠΉ ΠΏΠΎΠ»ΠΎΡΡΠΈ. ΠΠ½ΡΡΡΠΈΠΏΠ»Π΅Π²ΡΠ°Π»ΡΠ½ΠΎΠ΅ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΠ΅ ΡΠ²Π΅ΠΆΠ΅Π·Π°ΠΌΠΎΡΠΎΠΆΠ΅Π½Π½ΠΎΠΉ ΠΏΠ»Π°Π·ΠΌΡ, Π°ΠΊΡΠΈΠ²ΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠΉ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠ°ΠΌΠΈ ΡΡΡΠ΅ΠΏΡΠΎΠΊΠΈΠ½Π°Π·Ρ, ΠΏΠΎΠ·Π²ΠΎΠ»ΡΠ΅Ρ Π·Π½Π°ΡΠΈΡΠ΅Π»ΡΠ½ΠΎ ΠΏΠΎΠ²ΡΡΠΈΡΡ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ ΠΊΠΎΠ½ΡΠ΅ΡΠ²Π°ΡΠΈΠ²Π½ΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ Ρ Π±ΠΎΠ»ΡΠ½ΡΡ
Π‘Π ΠΈ ΡΠ»ΡΡΡΠΈΡΡ ΠΈΡΡ
ΠΎΠ΄Ρ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ
Evaluation of Effectiveness of Yersinia pestis Molecular Diagnostics in the Field Material from Sarydzhas Focus in Kyrgyzstan
Objective of the study is to assess the effectiveness of the methods for molecular diagnostics and identification of Yersinia pestis strains in the field material obtained from Sarydzhas high-mountain focus in Kyrgyz Republic. Materials and methods. Investigated were the samples of the field material, isolated in 2016 in Sarydzhas high-mountain plague focus, using conventional methods of laboratory diagnostics and PCR with hybridization-fluorescent and electrophoretic registration of results. Results and conclusions. It is demonstrated that in a number of cases molecular-genetic method has a higher resolution as compared to conventional methods of laboratory diagnostics of plague. It proves the necessity of wider usage of molecular-diagnostic methods in epizootiological monitoring of plague in natural foci in Kyrgyz Republic
ΠΠ‘ΠΠΠΠ« ΠΠ‘ΠΠΠΠ¬ΠΠΠΠΠΠΠ― ΠΠΠΠΠΠ’ΠΠ-Π ΠΠΠΠΠΠΠ‘ΠΠΠ Π’ΠΠΠΠΠ ΠΠ€ΠΠ ΠΠ Π Π ΠΠΠ ΠΠ ΠΠΠ‘Π’ΠΠ’ΠΠΠ¬ΠΠΠ ΠΠΠΠΠΠ«
The article discusses the possibilities of basic MRI techniques in primary prostate cancer diagnosis based on the MRI characteristics of anatomical and histological features of prostate. The assesment of prostate cancer distribution, stratification of risk for progression and the decision for treatment tactics, in accompanying of remedial actions, in treatment effectiveness monitoring and in early detection of relapses is discussed.ΠΠ° ΠΎΡΠ½ΠΎΠ²Π΅ ΡΠΏΠ΅ΡΠΈΡΠΈΠΊΠΈ ΠΎΡΠΎΠ±ΡΠ°ΠΆΠ΅Π½ΠΈΡ ΠΏΡΠΈ ΠΠ Π’ Π°Π½Π°ΡΠΎΠΌΠΎ-Π³ΠΈΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΎΡΠΎΠ±Π΅Π½Π½ΠΎΡΡΠ΅ΠΉ ΡΡΡΠΎΠ΅Π½ΠΈΡ ΠΏΡΠ΅Π΄ΡΡΠ°ΡΠ΅Π»ΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ, Π° ΡΠ°ΠΊΠΆΠ΅ ΡΠΈΠ·ΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΏΡΠΈΠ½ΡΠΈΠΏΠΎΠ² ΠΏΠΎΠ»ΡΡΠ΅Π½ΠΈΡ ΡΠΎΠΎΡΠ²Π΅ΡΡΡΠ²ΡΡΡΠΈΡ
ΠΈΠ·ΠΎΠ±ΡΠ°ΠΆΠ΅Π½ΠΈΠΉ ΠΏΡΠ΅Π΄ΡΡΠ°Π²Π»Π΅Π½ΠΎ ΠΎΠ±ΡΡΠΆΠ΄Π΅Π½ΠΈΠ΅ Π²ΠΎΠ·ΠΌΠΎΠΆΠ½ΠΎΡΡΠ΅ΠΉ ΠΎΡΠ½ΠΎΠ²Π½ΡΡ
ΠΌΠ΅ΡΠΎΠ΄ΠΈΠΊ ΠΠ Π’ Π² ΠΏΠ΅ΡΠ²ΠΈΡΠ½ΠΎΠΉ Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΠΊΠ΅ ΡΠ°ΠΊΠ° ΠΏΡΠΎΡΡΠ°ΡΡ, Π² ΠΎΡΠ΅Π½ΠΊΠ΅ Π΅Π³ΠΎ ΡΠ°ΡΠΏΡΠΎΡΡΡΠ°Π½Π΅Π½ΠΈΡ, Π² ΡΡΡΠ°ΡΠΈΡΠΈΠΊΠ°ΡΠΈΠΈ ΡΠΈΡΠΊΠ° ΠΏΡΠΎΠ³ΡΠ΅ΡΡΠΈΡΠΎΠ²Π°Π½ΠΈΡ ΠΈ ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΠΈ Π»Π΅ΡΠ΅Π±Π½ΠΎΠΉ ΡΠ°ΠΊΡΠΈΠΊΠΈ, ΠΏΡΠΈ ΡΠΎΠΏΡΠΎΠ²ΠΎΠΆΠ΄Π΅Π½ΠΈΠΈ Π»Π΅ΡΠ΅Π±Π½ΡΡ
ΠΌΠ΅ΡΠΎΠΏΡΠΈΡΡΠΈΠΉ, Π² ΠΊΠΎΠ½ΡΡΠΎΠ»Π΅ ΠΈΡ
ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ, Π° ΡΠ°ΠΊΠΆΠ΅ Π² ΡΠ°Π½Π½Π΅ΠΌ Π²ΡΡΠ²Π»Π΅Π½ΠΈΠΈ ΡΠ΅ΡΠΈΠ΄ΠΈΠ²ΠΎΠ²
- β¦